ZIM
REGN icon

Zacks Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Zacks Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-364
Closed -$262K – 691
2023
Q2 		$262K Sell
364
-33
-8% -$25.4K ﹤0.01% 552
2023
Q1 		$326K Sell
397
-18
-4% -$13.6K ﹤0.01% 505
2022
Q4 		$299K Sell
415
-141
-25% -$104K ﹤0.01% 501
2022
Q3 		$383K Sell
556
-55
-9% -$34.6K 0.01% 456
2022
Q2 		$361K Sell
611
-13,232
-96% -$8.6M 0.01% 463
2022
Q1 		$9.67M Buy
13,843
+1,099
+9% +$695K 0.13% 142
2021
Q4 		$8.05M Buy
12,744
+964
+8% +$593K 0.11% 157
2021
Q3 		$7.13M Buy
11,780
+859
+8% +$533K 0.11% 159
2021
Q2 		$6.1M Buy
10,921
+806
+8% +$408K 0.1% 164
2021
Q1 		$4.79M Buy
+10,115
New +$4.92M 0.09% 178
2018
Q4 		– Sell
-594
Closed -$240K – 574
2018
Q3 		$240K Buy
+594
New +$226K 0.01% 482
2015
Q1 		– Sell
-1,203
Closed -$494K – 692
2014
Q4 		$494K Buy
+1,203
New +$473K 0.02% 416

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Zacks Investment Management's REGN Position: Q3 2023 in Review

Zacks Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 364 shares — an estimated $262K sold.

Zacks Investment Management first reported a position in REGN in Q4 2014 and held it in 12 quarters. The position peaked at $9.67M in Q1 2022. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Zacks Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Zacks Investment Management sold 364 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $262K.
  • Zacks Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 12 quarters.
  • Zacks Investment Management's Regeneron Pharmaceuticals position peaked at $9.67M in Q1 2022.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Zacks Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.